Vistin Pharma ASA (STU:VP4)

Q4 2025 Vistin Pharma ASA Earnings Call Transcript

Feb 12, 2026 / 07:30 AM GMT

Release Date Price: €1.86 (+0.82%)

Transcript

Key Points

Positve

Vistin Pharma ASA (LTS:0RAM) achieved a record high sales volume of 1,520 metric tons in Q4 2025, marking a 9% increase compared to the same quarter in 2024.
The company reported a full-year revenue of NOK 452 million for 2025, up from NOK 430 million in 2024, reflecting a 5% increase.
Earnings per share for 2025 increased by 19% to NOK 1.69 compared to NOK 1.42 in the previous year.
Vistin Pharma ASA (LTS:0RAM) maintains a strong balance sheet with an equity ratio over 75% and a net cash position of NOK 16 million as of year-end.
The board of directors proposed an ordinary cash dividend of up to NOK 1.5 per share, indicating confidence in the company's financial health and future prospects.

Negative

Revenue for Q4 2025 decreased to NOK 111 million from NOK 140 million in Q4 2024, a decline attributed to lower global metformin prices.
EBITDA for Q4 2025 was NOK 26 million, down from NOK 28 million in the same quarter of the previous year.
The company incurred costs of approximately NOK 800,000 due to production disruptions caused by a weather storm in Norway.
The spot price of metformin fluctuates with global raw material prices, impacting revenue and purchasing effects.
There is ongoing competition from Asian manufacturers in the metformin market, although Vistin Pharma ASA (LTS:0RAM) positions itself as a premium supplier.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

VISTN.OL - Vistin Pharma ASA
Q4 2025 Vistin Pharma ASA Earnings Call
Feb 12, 2026 / 07:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and thank you for standing by. Welcome to the Visiting Pharma Quarterly Report Q4 2025 conference call. At this time, all participants are in the listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 1 and 1 again. Alternatively, you may submit your question via the webcast. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Maglus Toleo, CEO. Please go ahead.

-------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.